908 Devices (MASS) Aktievy
908 Devices Inc. tillhandahåller specialbyggda handhållna masspektrometriska och fouriertransform infraröda (FTIR) enheter för användning i viktiga hälso- och säkerhetsapplikationer. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 1/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
MASS Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
908 Devices Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$9.69 |
| 52 veckors högsta | US$11.25 |
| 52 veckors lägsta | US$5.03 |
| Beta | 0.68 |
| 1 månads förändring | 10.11% |
| 3 månaders förändring | 17.88% |
| 1 års förändring | 70.00% |
| 3 års förändring | 51.17% |
| 5 års förändring | -73.63% |
| Förändring sedan börsintroduktionen | -80.22% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Sep 09
MASS: Higher 2026 Revenue Outlook Will Support A Stronger Share Price
Analysts have raised the 908 Devices fair value estimate from $11 to $13, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E that shift their overall price target framework. What’s in the News for 908 Devices 908 Devices updated full year 2026 earnings guidance, setting a revenue range of $68.0 million to $70.0 million and lifting the lower end from $67.0 million.
Uppdatering av berättelse • Aug 26
MASS: Raised 2026 Outlook And Index Removals Will Shape Future P/E
Analysts have raised their fair value estimate for 908 Devices from $10 to $12, citing updates to key assumptions, including the discount rate, revenue growth outlook, profit margin profile, and future P/E expectations. What’s in the News for 908 Devices 908 Devices updated its full year 2026 revenue guidance to a range of $68.0 million to $70.0 million, compared with the previous range of $67.0 million to $70.0 million.Seeking Alpha • Aug 12
908 Devices: Mission Critical Devices Drive Growth
Summary 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M. Valuation remains reasonable at 5.5x forward P/S, supported by a $101.5M cash position, no debt, and narrowing EBITDA losses. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 12
MASS: Index Removals Will Set Up A Future Repricing Opportunity
Analysts have updated their fair value estimate for 908 Devices from $12.00 to $14.00, reflecting revised assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for 908 Devices 908 Devices was dropped from the Russell 2500 Growth Benchmark, according to index classification data.Recent updates
Uppdatering av berättelse • Sep 09
MASS: Higher 2026 Revenue Outlook Will Support A Stronger Share Price
Analysts have raised the 908 Devices fair value estimate from $11 to $13, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E that shift their overall price target framework. What’s in the News for 908 Devices 908 Devices updated full year 2026 earnings guidance, setting a revenue range of $68.0 million to $70.0 million and lifting the lower end from $67.0 million.Uppdatering av berättelse • Aug 26
MASS: Raised 2026 Outlook And Index Removals Will Shape Future P/E
Analysts have raised their fair value estimate for 908 Devices from $10 to $12, citing updates to key assumptions, including the discount rate, revenue growth outlook, profit margin profile, and future P/E expectations. What’s in the News for 908 Devices 908 Devices updated its full year 2026 revenue guidance to a range of $68.0 million to $70.0 million, compared with the previous range of $67.0 million to $70.0 million.Seeking Alpha • Aug 12
908 Devices: Mission Critical Devices Drive Growth
Summary 908 Devices is rated BUY after a 2Q26 earnings beat, strong revenue growth, and a 97% YTD share price gain. MASS benefits from robust demand for chemical detection devices, driven by law enforcement, defense, and volatile geopolitical conditions. Recurring revenue from NIRLab and product upgrades like VipIR underpin stable growth; management raised FY26 revenue guidance to $68–$70M. Valuation remains reasonable at 5.5x forward P/S, supported by a $101.5M cash position, no debt, and narrowing EBITDA losses. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 12
MASS: Index Removals Will Set Up A Future Repricing Opportunity
Analysts have updated their fair value estimate for 908 Devices from $12.00 to $14.00, reflecting revised assumptions around revenue growth, profit margins, discount rates, and future P/E expectations. What’s in the News for 908 Devices 908 Devices was dropped from the Russell 2500 Growth Benchmark, according to index classification data.Uppdatering av berättelse • Jun 18
MASS: Raised 2026 Revenue Outlook Will Support A Higher Stock Price
Analysts have lifted their price target on 908 Devices stock from $10.00 to $11.00, citing updated assumptions around fair value, revenue growth, discount rate and future P/E that they consider better aligned with the company's current outlook. What’s in the News for 908 Devices 908 Devices raised its full year 2026 revenue guidance, according to a key developments summary.Uppdatering av berättelse • Jun 03
MASS: Raised 2026 Revenue Outlook Will Support Higher Future P/E Multiple
Analysts have modestly adjusted their price targets on 908 Devices, reflecting updated assumptions for a fair value of $10.00, a slightly higher discount rate, marginally stronger projected revenue growth, a softer profit margin outlook, and a higher future P/E of about 70x. What's in the News 908 Devices raised its full year 2026 revenue guidance to a range of $67.0 million to $70.0 million.Uppdatering av berättelse • May 12
MASS: Raised 2026 Revenue Guidance Will Support Higher Earnings Multiple
Analysts have reset their price target on 908 Devices to $10.00 from $8.00, citing updated assumptions around revenue growth, profitability, and future P/E that feed into a higher fair value estimate and a modestly higher discount rate. What's in the News 908 Devices raised full year 2026 revenue guidance to a range of $67.0 million to $70.0 million, compared with 2025 revenue, with the range described as representing 19% to 25% growth (Corporate Guidance: Raised).Analysartikel • Jan 23
908 Devices Inc.'s (NASDAQ:MASS) 29% Price Boost Is Out Of Tune With Revenues
Those holding 908 Devices Inc. ( NASDAQ:MASS ) shares would be relieved that the share price has rebounded 29% in the...Analysartikel • Nov 12
Some 908 Devices Inc. (NASDAQ:MASS) Shareholders Look For Exit As Shares Take 26% Pounding
908 Devices Inc. ( NASDAQ:MASS ) shareholders won't be pleased to see that the share price has had a very rough month...Analysartikel • Sep 20
908 Devices Inc.'s (NASDAQ:MASS) Share Price Not Quite Adding Up
When close to half the companies in the Electronic industry in the United States have price-to-sales ratios (or "P/S...Analysartikel • Aug 07
908 Devices Inc. (NASDAQ:MASS) Analysts Are Pretty Bullish On The Stock After Recent Results
NasdaqGM:MASS 1 Year Share Price vs Fair Value Explore 908 Devices's Fair Values from the Community and select yours...Uppdatering av berättelse • Aug 06
US Federal And International Funding Will Expand Global Analysis Markets
The notable increase in 908 Devices’ price target reflects improved outlook due to higher expected revenue growth and an expanded forward P/E, raising the consensus fair value from $6.50 to $9.00. What's in the News 908 Devices raised its 2025 revenue guidance to $54–56 million (13–17% growth), up from prior guidance of $53–55 million.Analysartikel • Jun 11
908 Devices Inc.'s (NASDAQ:MASS) Shares Climb 26% But Its Business Is Yet to Catch Up
Despite an already strong run, 908 Devices Inc. ( NASDAQ:MASS ) shares have been powering on, with a gain of 26% in the...
Ny berättelse • Apr 06
The New Handheld Mass Spectrometer Launch Will Expand Market Reach
Divesting the desktop bioprocessing portfolio boosts cash reserves, streamlines operations, and is expected to enhance margins and cash flow in future years.Seeking Alpha • Mar 06
908 Devices Makes Key Divestiture (Rating Upgrade)
Summary 908 Devices' stock surged after announcing a $70 million desktop portfolio sale, doubling its cash position and improving financial stability. The company will now focus on its handheld device business, expecting 11% to 15% revenue growth in 2025 with acceleration in 2026. MASS management believes losses will be significantly reduced with the new structure, with positive cash flow next year. Read the full article on Seeking AlphaAnalysartikel • Mar 05
908 Devices Inc.'s (NASDAQ:MASS) 55% Jump Shows Its Popularity With Investors
The 908 Devices Inc. ( NASDAQ:MASS ) share price has done very well over the last month, posting an excellent gain of...Analysartikel • Nov 15
Earnings Update: 908 Devices Inc. (NASDAQ:MASS) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on 908 Devices Inc. ( NASDAQ:MASS ), given that the company fell short...Seeking Alpha • Sep 08
908 Devices: Key Investor Now Selling
Summary ARK Invest's recent sales of 908 Devices shares have helped to send the stock to multi-year lows. 908 Devices is seeing decent revenue growth, but large losses and limited financial flexibility raise concerns about future capital needs. The stock's low valuation compared to peers is a positive, but ongoing sales by ARK Invest could exert further downward pressure. Read the full article on Seeking AlphaAnalysartikel • Aug 16
Why We're Not Concerned Yet About 908 Devices Inc.'s (NASDAQ:MASS) 29% Share Price Plunge
To the annoyance of some shareholders, 908 Devices Inc. ( NASDAQ:MASS ) shares are down a considerable 29% in the last...Analysartikel • Mar 30
We Think 908 Devices (NASDAQ:MASS) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysartikel • Dec 18
Investors Appear Satisfied With 908 Devices Inc.'s (NASDAQ:MASS) Prospects
When you see that almost half of the companies in the Electronic industry in the United States have price-to-sales...Aktieägarnas avkastning
| MASS | US Electronic | US Marknad | |
|---|---|---|---|
| 7D | -6.2% | 4.9% | -0.2% |
| 1Y | 70.0% | 47.7% | 14.8% |
Avkastning vs industri: MASS översteg US Electronic branschen som gav 47.7 % under det senaste året.
Avkastning vs Marknaden: MASS översteg US marknaden som gav 14.8 % under det senaste året.
Prisvolatilitet
| MASS volatility | |
|---|---|
| MASS Average Weekly Movement | 7.6% |
| Electronic Industry Average Movement | 9.4% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stabil aktiekurs: MASS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: MASS s veckovolatilitet ( 8% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2012 | 172 | Kevin Knopp | 908devices.com |
908 Devices Inc. tillhandahåller specialbyggda handhållna masspektrometri- och fouriertransforminfraröda (FTIR) enheter för användning i viktiga hälso- och säkerhetsapplikationer. Bolagets produkter inkluderar MX908, en handhållen, batteridriven Mass Spec-enhet som är utformad för snabb analys av fasta, flytande, ång- och aerosolmaterial med okänd identitet; XplorIR, en handhållen enhet som använder FTIR-spektroskopi för att identifiera, kvantifiera och spåra gaser och ångor; ThreatID, en bärbar FTIR-enhet som snabbt upptäcker och identifierar cirka 28.000 okända kemiska faror i form av gas, ånga, pulver och vätska; ProtectIR, en handhållen FTIR-enhet som kan identifiera cirka 23.000 kemiska faror i fast och flytande form; och VipIR, en handhållen 3-i-1-analysator som integrerar FTIR, Raman-spektroskopi och smart spektralbehandling (SSP), en egenutvecklad algoritm, för att ge ett enda resultat från bara ett prov. Verksamheten bedrivs i USA, Europa, Mellanöstern, Afrika, Asien och Stillahavsområdet samt övriga Amerika.
908 Devices Inc. Sammanfattning av grunderna
| MASS grundläggande statistik | |
|---|---|
| Börsvärde | US$405.48m |
| Vinst(TTM) | -US$34.38m |
| Intäkter(TTM) | US$60.84m |
6.6x
P/S-förhållande-11.6x
P/E-förhållandeÄr MASS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| MASS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$60.84m |
| Kostnad för intäkter | US$28.81m |
| Bruttovinst | US$32.03m |
| Övriga kostnader | US$66.41m |
| Intäkter | -US$34.38m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.83 |
| Bruttomarginal | 52.65% |
| Nettovinstmarginal | -56.51% |
| Skuld/egenkapitalförhållande | 0% |
Hur har MASS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/09 18:20 |
| Aktiekurs vid dagens slut | 2026/09/09 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
908 Devices Inc. bevakas av 5 analytiker. 5 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Puneet Souda | Leerink Partners LLC |
| Max Masucci | Roth Capital Partners |
| Daniel Arias | Stifel, Equities Research |